Rallybio acquires Prophylix´ rare disease programs

av | aug 22, 2019 | News

Prophylix AS has just announced that the company in late June 2019 entered into a definitive agreement with Rallybio, a U.S.-based drug development company. Through the agreement Rallybio acquires two orphan drug programs from Prophylix AS, NAITgam and a follow-on...